pmc logo image
Logo of brjpharmJournal URL: http://www3.interscience.wiley.com/journal/121548564/home
Journal List > Br J Pharmacol > v.98(1); Sep 1989

Formats:
Br J Pharmacol. 1989 September; 98(1): 119–126.
PMCID: PMC1854673
Copyright notice
Comparative effects of bepridil, its quaternary derivative CERM 11888 and verapamil on caffeine-induced contracture in ferret hearts.
J. Leboeuf, C. Leoty, J. C. Lamar, and R. Massingham
Department of Pharmacology, RL-CERM, Riom, France.
Abstract
1. The effects of bepridil, its quaternary derivative: CERM 11888 (methyl-pyrrolidinium bromide) (10(-7)-10(-5) M), and verapamil (10(-7)-10(-6) M) were compared on caffeine-induced contracture of isolated ventricular trabeculae of the ferret. 2. Bepridil diminished the amplitude of contracture in a concentration-dependent fashion, and this effect was significantly different from that of CERM 11888 which, like verapamil, only reduced the amplitude at the highest concentration used. 3. Bepridil (10(-6) M) significantly shortened the time to peak tension and accelerated the relaxation phase of contracture. This latter effect was different from that of CERM 11888. Verapamil (10(-6) M) also tended to accelerate the relaxation phase. At 10(-5) M these actions of bepridil on the time to peak and relaxation tended to reverse. 4. At all concentrations bepridil and verapamil reduced the rate of repriming of contracture and this effect of bedpridil was significantly different from that of its quaternary derivative which only showed a significant effect at 10(-5) M. 5. These results demonstrate a clear intracellular effect of bepridil in the ferret heart. Verapamil and CERM 11888 had only weak intracellular effects even at high concentrations. 6. Analysis of the results suggests that the main sites of action of bepridil in this model are the sarcoplasmic reticulum and one or two calcium compartments in the sarcolemma.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 119
119
icon of scanned page 120
120
icon of scanned page 121
121
icon of scanned page 122
122
icon of scanned page 123
123
icon of scanned page 124
124
icon of scanned page 125
125
icon of scanned page 126
126
 
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Alpert JS, Coumel P, Greeff K, Krikler DM, Remme WJ, Schönbaum E, Verduyn CW. Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties. Pharmatherapeutica. 1985;4(4):195–222. [PubMed]
  • Van Amsterdam FT, Zaagsma J. Modulation of ATP-dependent calcium extrusion and Na+/Ca2+ exchange across rat cardiac sarcolemma by calcium antagonists. Eur J Pharmacol. 1986 Apr 29;123(3):441–449. [PubMed]
  • Bers DM. Ryanodine and the calcium content of cardiac SR assessed by caffeine and rapid cooling contractures. Am J Physiol. 1987 Sep;253(3 Pt 1):C408–C415. [PubMed]
  • Brown J, Marshall RJ, Winslow E. Effects of selective channel blocking agents on contractions and action potentials in K+-depolarized guinea-pig atria. Br J Pharmacol. 1985 Sep;86(1):7–17. [PubMed]
  • Chapman RA. Control of cardiac contractility at the cellular level. Am J Physiol. 1983 Oct;245(4):H535–H552. [PubMed]
  • Chapman RA, Léoty C. Similarities between the potassium contractures and those induced by hypertonic solutions in rat ventricular trabeculae. J Physiol. 1974 Mar;237(2):28P–30P. [PubMed]
  • Chapman RA, Léoty C. The time-dependent and dose-dependent effects of caffeine on the contraction of the ferret heart. J Physiol. 1976 Apr;256(2):287–314. [PubMed]
  • Clusin WT. Do caffeine and metabolic inhibitors increase free calcium in the heart? Interpretation of conflicting intracellular calcium measurements. J Mol Cell Cardiol. 1985 Mar;17(3):213–220. [PubMed]
  • Cramb G, Dow JW. Uptake of bepridil into isolated ventricular myocytes. Retention by actin. Biochem Pharmacol. 1983 Jan 15;32(2):227–231. [PubMed]
  • Hunter DR, Haworth RA, Berkoff HA. Cellular calcium turnover in the perfused rat heart: modulation by caffeine and procaine. Circ Res. 1982 Sep;51(3):363–370. [PubMed]
  • Itoh H, Ishikawa T, Hidaka H. Effects on calmodulin of bepridil, an antianginal agent. J Pharmacol Exp Ther. 1984 Sep;230(3):737–741. [PubMed]
  • Itoh H, Tanaka T, Mitani Y, Hidaka H. The binding of the calcium channel blocker, bepridil, to calmodulin. Biochem Pharmacol. 1986 Jan 15;35(2):217–220. [PubMed]
  • Konishi M, Kurihara S, Sakai T. The effects of caffeine on tension development and intracellular calcium transients in rat ventricular muscle. J Physiol. 1984 Oct;355:605–618. [PubMed]
  • Labrid C, Grosset A, Dureng G, Mironneau J, Duchene-Marullaz P. Some membrane interactions with bepridil, a new antianginal agent. J Pharmacol Exp Ther. 1979 Dec;211(3):546–554. [PubMed]
  • Lamers JM, Cysouw KJ, Verdouw PD. Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837–3843. [PubMed]
  • Lynch JJ, Rahwan RG, Lucchesi BR. Antifibrillatory actions of bepridil and butyl-MDI, two intracellular calcium antagonists. Eur J Pharmacol. 1985 Apr 23;111(1):9–15. [PubMed]
  • MacLeod KT, Bers DM. Effects of rest duration and ryanodine on changes of extracellular [Ca] in cardiac muscle from rabbits. Am J Physiol. 1987 Sep;253(3 Pt 1):C398–C407. [PubMed]
  • Movsesian MA, Ambudkar IS, Adelstein RS, Shamoo AE. Stimulation of canine cardiac sarcoplasmic reticulum Ca2+ uptake by dihydropyridine Ca2+ antagonists. Biochem Pharmacol. 1985 Jan 15;34(2):195–201. [PubMed]
  • Mras S, Sperelakis N. Comparison of [3H]bepridil and [3H]verapamil uptake into rabbit aortic rings. J Cardiovasc Pharmacol. 1982 Sep–Oct;4(5):777–783. [PubMed]
  • Pang DC, Sperelakis N. Inhibitory action of bepridil (CERM-1978) on calcium binding to cardiac sarcolemma of guinea pig. Biochem Pharmacol. 1981 Aug 15;30(16):2356–2358. [PubMed]
  • Pang DC, Sperelakis N. Differential actions of calcium antagonists on calcium binding to cardiac sarcolemma. Eur J Pharmacol. 1982 Jul 16;81(3):403–409. [PubMed]
  • Pang DC, Sperelakis N. Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscles. Eur J Pharmacol. 1983 Feb 18;87(2-3):199–207. [PubMed]
  • Pang DC, Sperelakis N. Uptake of calcium antagonistic drugs into muscles as related to their lipid solubilities. Biochem Pharmacol. 1984 Mar 1;33(5):821–826. [PubMed]
  • Raess BU, Gersten MH. Calmodulin-stimulated plasma membrane (Ca2+ + Mg2+)-ATPase: inhibition by calcium channel entry blockers. Biochem Pharmacol. 1987 Aug 1;36(15):2455–2459. [PubMed]
  • Rasmussen CA, Jr, Sutko JL, Barry WH. Effects of ryanodine and caffeine on contractility, membrane voltage, and calcium exchange in cultured heart cells. Circ Res. 1987 Apr;60(4):495–504. [PubMed]
  • Schaeffer P, Baissat J, Dureng G, Lamar JC, Stoclet JC. Effects of bepridil and of its quaternary derivative on rat tail artery. Eur J Pharmacol. 1986 Apr 9;123(1):155–159. [PubMed]
  • Silver PJ, Pinto PB, Dachiw J. Modulation of vascular and cardiac contractile protein regulatory mechanisms by calmodulin inhibitors and related compounds. Biochem Pharmacol. 1986 Aug 1;35(15):2545–2551. [PubMed]
  • Singh BN, Baky S, Nademanee K. Second-generation calcium antagonists: search for greater selectivity and versatility. Am J Cardiol. 1985 Jan 25;55(3):214B–221B. [PubMed]
  • Singh BN, Nademanee K, Feld G, Piontek M, Schwab M. Comparative electrophysiologic profiles of calcium antagonists with particular reference to bepridil. Am J Cardiol. 1985 Mar 15;55(7):14C–19C. [PubMed]
  • Solaro RJ, Bousquet P, Johnson JD. Stimulation of cardiac myofilament force, ATPase activity and troponin C Ca++ binding by bepridil. J Pharmacol Exp Ther. 1986 Aug;238(2):502–507. [PubMed]
  • Vogel S, Crampton R, Sperelakis N. Blockade of myocardial slow channels by bepridil (CERM-1978). J Pharmacol Exp Ther. 1979 Sep;210(3):378–385. [PubMed]
  • Wahler GM, Doane JD, Ousterhout JM, Sperelakis N, Lamar JC, Busch N, Biswas JC, Rogers TB. Effect of methylated bepridil on slow action potentials in cardiac muscle and vascular smooth muscle. Biochem Pharmacol. 1986 Jul 15;35(14):2337–2343. [PubMed]
  • Wang T, Tsai LI, Schwartz A. Effects of verapamil, diltiazem, nisoldipine and felodipine on sarcoplasmic reticulum. Eur J Pharmacol. 1984 May 4;100(3-4):253–261. [PubMed]
  • Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther. 1986 Apr;237(1):9–17. [PubMed]
  • Younès A, Fontanarava C, Schneider JM. Effects of bepridil on the Ca-dependent ATPase activity of sarcoplasmic reticulum. Biochem Pharmacol. 1981 Nov 1;30(21):2979–2982. [PubMed]
  • Younes A, Schneider JM. Effects of bepridil on Ca2+ uptake by cardiac mitochondria. Biochem Pharmacol. 1984 Apr 15;33(8):1363–1366. [PubMed]
Articles from British Journal of Pharmacology are provided here courtesy of
The British Pharmacological Society

PubMed articles by these authors